《公司業績》百威亞太(01876.HK)中期純利1.85億美元跌70% 不派息
百威亞太(01876.HK)公布截至今年6月底止中期業績,營業額25.75億美元(下同),按年跌26.9%。純利1.85億元,按年跌69.5%;每股盈利1.4仙,不派息。而股東應佔正常化溢利由 2019年上半年的6.51億美元減少至今年上半年的2.22億美元,主因正常化除息稅折舊攤銷前盈利下跌,以及主要受不利匯率
影響導致淨融資成本增加。
於上半年,集團總銷量按年減少22.2%,於第二季則按年減少6.1%,主要是由於中國強勁復甦。毛利率按年下跌2.41個百分點至51.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.